

# Jens Bedke

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8511426/publications.pdf>

Version: 2024-02-01

250  
papers

14,763  
citations

76326

40  
h-index

22166

113  
g-index

285  
all docs

285  
docs citations

285  
times ranked

12581  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2019, 380, 1116-1127.	27.0	2,319
2	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2019, 380, 1103-1115.	27.0	1,824
3	Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2017, 18, 312-322.	10.7	1,388
4	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2021, 384, 829-841.	27.0	961
5	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. New England Journal of Medicine, 2021, 384, 1289-1300.	27.0	956
6	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet, The, 2019, 393, 2404-2415.	13.7	778
7	European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. European Urology, 2022, 82, 399-410.	1.9	485
8	Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2020, 21, 1563-1573.	10.7	466
9	Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. New England Journal of Medicine, 2021, 385, 683-694.	27.0	394
10	Economic aspects of bladder cancer: what are the benefits and costs?. World Journal of Urology, 2009, 27, 295-300.	2.2	378
11	Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 525-537.	10.7	225
12	IMA901, a multi-peptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 1599-1611.	10.7	181
13	Systemic therapy in metastatic renal cell carcinoma. World Journal of Urology, 2017, 35, 179-188.	2.2	117
14	The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naïve Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care. European Urology, 2021, 80, 393-397.	1.9	103
15	Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma. European Urology, 2021, 79, 339-342.	1.9	98
16	Novel multi-peptide vaccination in HLA-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate, 2009, 69, 917-927.	2.3	97
17	Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction. BJU International, 2007, 100, 639-645.	2.5	92
18	DNA Methylation of the <i>SLC16A3</i> Promoter Regulates Expression of the Human Lactate Transporter MCT4 in Renal Cancer with Consequences for Clinical Outcome. Clinical Cancer Research, 2013, 19, 5170-5181.	7.0	90

#	ARTICLE	IF	CITATIONS
19	Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.. Journal of Clinical Oncology, 2019, 37, 4500-4500.	1.6	85
20	Physical and Biological Characterization of Superparamagnetic Iron Oxide- and Ultrasmall Superparamagnetic Iron Oxide-Labeled Cells. Investigative Radiology, 2005, 40, 504-513.	6.2	84
21	Wnt Pathway Regulation in Chronic Renal Allograft Damage. American Journal of Transplantation, 2009, 9, 2223-2239.	4.7	80
22	mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer. Human Vaccines and Immunotherapeutics, 2014, 10, 3146-3152.	3.3	74
23	1306: Tumor-Size Breakpoint for Prognostic Stratification of Localized Renal Cell Carcinoma (RCC). Journal of Urology, 2007, 177, 430-430.	0.4	68
24	PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma. Cancer Immunology Research, 2019, 7, 1891-1899.	3.4	66
25	Perinephric and renal sinus fat infiltration in pT3a renal cell carcinoma: possible prognostic differences. BJU International, 2009, 103, 1349-1354.	2.5	63
26	Liquid biopsy: ready to guide therapy in advanced prostate cancer?. BJU International, 2016, 118, 855-863.	2.5	61
27	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2020, 21, 105-120.	10.7	61
28	Beneficial Effects of CCR1 Blockade on the Progression of Chronic Renal Allograft Damage. American Journal of Transplantation, 2007, 7, 527-537.	4.7	55
29	Impact of an Altered Wnt1/ $\beta$ 2-Catenin Expression on Clinicopathology and Prognosis in Clear Cell Renal Cell Carcinoma. International Journal of Molecular Sciences, 2013, 14, 10944-10957.	4.1	55
30	Survival Prediction of Clear Cell Renal Cell Carcinoma Based on Gene Expression Similarity to the Proximal Tubule of the Nephron. European Urology, 2015, 68, 1016-1020.	1.9	55
31	Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer. Molecular Cancer Therapeutics, 2018, 17, 2746-2755.	4.1	53
32	The influence of body mass index on the long-term survival of patients with renal cell carcinoma after tumour nephrectomy. BJU International, 2008, 101, 1243-1246.	2.5	51
33	Cisplatin Hypersensitivity of Testicular Germ Cell Tumors Is Determined by High Constitutive Noxa Levels Mediated by Oct-4. Cancer Research, 2013, 73, 1460-1469.	0.9	50
34	EAU Policy on Live Surgery Events. European Urology, 2014, 66, 87-97.	1.9	50
35	Minimally invasive percutaneous nephrolithotomy: an alternative to retrograde intrarenal surgery and shockwave lithotripsy. World Journal of Urology, 2013, 31, 1555-1561.	2.2	48
36	Testicular seminoma clinical stage 1: treatment outcome on a routine care level. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1599-1607.	2.5	48

#	ARTICLE	IF	CITATIONS
37	Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.. Journal of Clinical Oncology, 2021, 39, 308-308.	1.6	48
38	Minimally invasive percutaneous nephrolitholapaxy (PCNL) as an effective and safe procedure for large renal stones. BJU International, 2012, 110, E1022-6.	2.5	46
39	MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients. Oncotarget, 2016, 7, 78433-78447.	1.8	45
40	Minimally Invasive Percutaneous Nephrolithotomy: A Comparative Study of the Management of Small and Large Renal Stones. Urology, 2013, 81, 241-245.	1.0	43
41	Expression of stage-specific embryonic antigen-4 (SSEA-4) defines spontaneous loss of epithelial phenotype in human solid tumor cells. Glycobiology, 2015, 25, 902-917.	2.5	42
42	Comprehensive Metabolomic and Lipidomic Profiling of Human Kidney Tissue: A Platform Comparison. Journal of Proteome Research, 2017, 16, 933-944.	3.7	41
43	Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma. International Journal of Cancer, 2018, 143, 3181-3193.	5.1	40
44	SIUâ€“ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. World Journal of Urology, 2019, 37, 61-83.	2.2	40
45	Incidental prostate cancer at radical cystoprostatectomy: implications for apexâ€“sparing surgery. BJU International, 2010, 105, 468-471.	2.5	39
46	Treatment of testicular intraepithelial neoplasia (intratubular germ cell neoplasia unspecified) with local radiotherapy or with platinum-based chemotherapy: A survey of the German Testicular Cancer Study Group. Annals of Oncology, 2013, 24, 1332-1337.	1.2	39
47	Prostate cancer detection in patients with prior negative biopsy undergoing cognitive-, robotic- or in-bore MRI target biopsy. World Journal of Urology, 2018, 36, 761-768.	2.2	38
48	Immunotherapy for kidney cancer. Current Opinion in Urology, 2018, 28, 8-14.	1.8	37
49	Can urinary biomarkers replace cystoscopy?. World Journal of Urology, 2019, 37, 1741-1749.	2.2	37
50	Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. European Urology, 2017, 72, 477-481.	1.9	36
51	Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin. European Urology Focus, 2019, 5, 608-618.	3.1	35
52	Prognostic Stratification of Localized Renal Cell Carcinoma by Tumor Size. Journal of Urology, 2008, 180, 62-67.	0.4	34
53	Peroxisome Proliferator-Activated Receptor (PPAR)Î³ Can Inhibit Chronic Renal Allograft Damage. American Journal of Pathology, 2010, 176, 2150-2162.	3.8	34
54	Prostate cancer gene 3 (PCA3) is of additional predictive value in patients with PI-RADS grade III (intermediate) lesions in the MR-guided re-biopsy setting for prostate cancer. World Journal of Urology, 2016, 34, 509-515.	2.2	34

#	ARTICLE	IF	CITATIONS
55	Expression of inhibitor of apoptosis protein Livin in renal cell carcinoma and non-tumorous adult kidney. British Journal of Cancer, 2007, 97, 1271-1276.	6.4	33
56	Analysis of Early Morbidity and Functional Outcome of Thulium: Yttrium-Aluminum-Garnet Laser Enucleation for Benign Prostate Enlargement: Patient Age and Prostate Size Determine Adverse Surgical Outcome. Urology, 2015, 85, 182-188.	1.0	33
57	Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy. Genome Medicine, 2020, 12, 32.	8.2	32
58	A novel CXCL8 protein-based antagonist in acute experimental renal allograft damage. Molecular Immunology, 2010, 47, 1047-1057.	2.2	30
59	Second-line systemic therapy for the treatment of metastatic renal cell cancer. Expert Review of Anticancer Therapy, 2012, 12, 777-785.	2.4	30
60	Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.. Journal of Clinical Oncology, 2019, 37, 4512-4512.	1.6	30
61	Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes. Scientific Reports, 2016, 6, 29930.	3.3	29
62	Transurethral Resection of Bladder Tumors: Next-generation Virtual Reality Training for Surgeons. European Urology Focus, 2019, 5, 906-911.	3.1	29
63	Intention-to-Treat Analysis of <sup>68</sup> Ga-PSMA and <sup>11</sup> C-Choline PET/CT Versus CT for Prostate Cancer Recurrence After Surgery. Journal of Nuclear Medicine, 2019, 60, 1359-1365.	5.0	29
64	2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma. European Urology, 2022, 81, 134-137.	1.9	29
65	Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. World Journal of Urology, 2014, 32, 31-38.	2.2	28
66	German second-opinion network for testicular cancer: Sealing the leaky pipe between evidence and clinical practice. Oncology Reports, 2014, 31, 2477-2481.	2.6	28
67	High cytoplasmic expression of p27 <sup>Kip1</sup> is associated with a worse cancer-specific survival in clear cell renal cell carcinoma. BJU International, 2012, 109, 1565-1570.	2.5	27
68	Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience. Therapeutic Advances in Urology, 2017, 9, 81-88.	2.0	27
69	ROLE OF XANTHINE OXIDOREDUCTASE IN EXPERIMENTAL ACUTE RENAL-ALLOGRAFT REJECTION. Transplantation, 2004, 77, 1683-1692.	1.0	26
70	Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression. Oncology Reports, 2010, 23, 159-63.	2.6	26
71	Epithelial cell adhesion molecule is an independent prognostic marker in clear cell renal carcinoma. International Journal of Cancer, 2013, 132, 2948-2955.	5.1	25
72	MCT4 surpasses the prognostic relevance of the ancillary protein CD147 in clear cell renal cell carcinoma. Oncotarget, 2015, 6, 30615-30627.	1.8	24

#	ARTICLE	IF	CITATIONS
73	Virtual Bladder Tumor Transurethral Resection: An Objective Evaluation Tool to Overcome Learning Curves with and without Photodynamic Diagnostics. <i>Urologia Internationalis</i> , 2011, 87, 138-142.	1.3	23
74	Met-RANTES Inhibition of Mucosal Perfusion Failure in Acute Intestinal Transplant Rejection – Role of Endothelial Cell-Leukocyte Interaction. <i>Journal of Vascular Research</i> , 2002, 39, 51-58.	1.4	22
75	En bloc stapler ligation of the renal vascular pedicle during laparoscopic nephrectomy. <i>BJU International</i> , 2008, 101, 878-882.	2.5	22
76	Rare and changeable as a chameleon: paraneoplastic syndromes in renal cell carcinoma. <i>World Journal of Urology</i> , 2018, 36, 849-854.	2.2	22
77	Targeted vs systematic robot-assisted transperineal magnetic resonance imaging–transrectal ultrasonography fusion prostate biopsy. <i>BJU International</i> , 2018, 121, 791-798.	2.5	22
78	Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice. <i>BJU International</i> , 2018, 121, 84-92.	2.5	22
79	Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer. <i>World Journal of Urology</i> , 2019, 37, 1773-1784.	2.2	22
80	STAT-1 decoy oligodeoxynucleotide inhibition of acute rejection in mouse heart transplants. <i>Basic Research in Cardiology</i> , 2009, 104, 719-729.	5.9	21
81	Suppression of Chronic Damage in Renal Allografts by Liver X Receptor (LXR) Activation. <i>American Journal of Pathology</i> , 2011, 179, 92-103.	3.8	21
82	Prolonged percutaneous <sup>SNM</sup> testing does not cause infection–related explanation. <i>BJU International</i> , 2013, 111, 485-491.	2.5	21
83	UCP-3 uncoupling protein confers hypoxia resistance to renal epithelial cells and is upregulated in renal cell carcinoma. <i>Scientific Reports</i> , 2015, 5, 13450.	3.3	21
84	Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer. <i>BJU International</i> , 2018, 122, 152-159.	2.5	21
85	SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). <i>European Journal of Cancer</i> , 2019, 107, 37-45.	2.8	21
86	Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. <i>Future Oncology</i> , 2021, 17, 3137-3150.	2.4	21
87	Transcripts of circulating tumor cells detected by a breast cancer-specific platform correlate with clinical stage in bladder cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1013-1020.	2.5	20
88	Nicotinamide–N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma. <i>Clinical and Translational Medicine</i> , 2022, 12, .	4.0	20
89	Feasibility of accelerated simultaneous multislice diffusion-weighted MRI of the prostate. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 1507-1515.	3.4	19
90	Performance of Urinary Markers for Detection of Upper Tract Urothelial Carcinoma: Is Upper Tract Urine More Accurate than Urine from the Bladder?. <i>Disease Markers</i> , 2018, 2018, 1-5.	1.3	19

#	ARTICLE	IF	CITATIONS
91	Role of multiparametric magnetic resonance imaging for patients under active surveillance for prostate cancer: a systematic review with diagnostic meta-analysis. Prostate Cancer and Prostatic Diseases, 2019, 22, 206-220.	3.9	19
92	Anti-Inflammatory Effects of $\alpha$ -v Integrin Antagonism in Acute Kidney Allograft Rejection. American Journal of Pathology, 2007, 171, 1127-1139.	3.8	17
93	STAT-1 decoy oligonucleotide improves microcirculation and reduces acute rejection in allogeneic rat small bowel transplants. Gene Therapy, 2007, 14, 883-890.	4.5	17
94	Human Pregnane X Receptor Genotype of the Donor but Not of the Recipient Is a Risk Factor for Delayed Graft Function After Renal Transplantation. Clinical Pharmacology and Therapeutics, 2012, 91, 905-916.	4.7	17
95	Inflammatory prognostic markers in clear cell renal cell carcinoma – preoperative $\alpha$ -reactive protein does not improve predictive accuracy. BJU International, 2012, 110, E771-7.	2.5	17
96	Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of metastatic renal cell carcinoma (SWITCH-II). Annals of Oncology, 2017, 28, v295.	1.2	17
97	Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases. European Urology Focus, 2019, 5, 604-607.	3.1	17
98	Simultaneous whole-body PET/MRI with integrated multiparametric MRI for primary staging of high-risk prostate cancer. World Journal of Urology, 2020, 38, 2513-2521.	2.2	17
99	Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma. Future Oncology, 2020, 16, 2307-2328.	2.4	17
100	Enfortumab vedotin – next game-changer in urothelial cancer. Expert Opinion on Biological Therapy, 2021, 21, 801-809.	3.1	17
101	Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial. European Urology Oncology, 2022, 5, 225-234.	5.4	17
102	Comparison of different concepts for interpretation of chromosomal aberrations in urothelial cells detected by fluorescence in situ hybridization. Journal of Cancer Research and Clinical Oncology, 2017, 143, 677-685.	2.5	16
103	mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance. Journal of Cancer Research and Clinical Oncology, 2019, 145, 153-163.	2.5	16
104	Prediction of Postoperative Risks in Laparoscopic Partial Nephrectomy Using RENAL, Mayo Adhesive Probability and Renal Pelvic Score. Anticancer Research, 2017, 37, 1369-1374.	1.1	16
105	High nuclear Livin expression is a favourable prognostic indicator in renal cell carcinoma. BJU International, 2008, 102, 1700-1706.	2.5	15
106	1.2 French stone retrieval baskets further enhance irrigation flow in flexible ureterorenoscopy. Urolithiasis, 2013, 41, 153-157.	2.0	15
107	17LBA Results from an open-label, randomized, controlled Phase 3 study investigating IMA901 multi-peptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC. European Journal of Cancer, 2015, 51, S718.	2.8	15
108	Seminoma Clinical Stage 1 - Patterns of Care in Germany. Urologia Internationalis, 2016, 96, 390-398.	1.3	15



#	ARTICLE	IF	CITATIONS
109	First report of robot-assisted transperineal fusion versus off-target biopsy in patients undergoing repeat prostate biopsy. <i>World Journal of Urology</i> , 2017, 35, 1023-1029.	2.2	15
110	Single-use versus reusable ureterorenoscopes for retrograde intrarenal surgery (RIRS): systematic comparative analysis of physical and optical properties in three different devices. <i>World Journal of Urology</i> , 2018, 36, 2059-2063.	2.2	15
111	Can contrast-enhanced ultrasound and acoustic radiation force impulse imaging characterize CT-indeterminate renal masses? A prospective evaluation with histological confirmation. <i>World Journal of Urology</i> , 2019, 37, 1339-1346.	2.2	15
112	Optimized protocol for metabolomic and lipidomic profiling in formalin-fixed paraffin-embedded kidney tissue by LC-MS. <i>Analytica Chimica Acta</i> , 2020, 1134, 125-135.	5.4	15
113	Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2022, 82, 427-439.	1.9	15
114	Adjuvant Treatment of High-risk Renal Cell Carcinoma: Leaving the Desert?. <i>European Urology</i> , 2017, 71, 695-696.	1.9	14
115	Immune checkpoint inhibition for the treatment of renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 83-94.	3.1	14
116	Immunologic mechanisms in RCC and allogeneic renal transplant rejection. <i>Nature Reviews Urology</i> , 2010, 7, 339-347.	3.8	13
117	Myoglobin expression in renal cell carcinoma is regulated by hypoxia. <i>Experimental and Molecular Pathology</i> , 2013, 95, 307-312.	2.1	13
118	Transketolase like 1 (TKTL1) expression alterations in prostate cancer tumorigenesis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 472.e21-472.e27.	1.6	13
119	Simultaneous Extraction of RNA and Metabolites from Single Kidney Tissue Specimens for Combined Transcriptomic and Metabolomic Profiling. <i>Journal of Proteome Research</i> , 2018, 17, 3039-3049.	3.7	13
120	Circulating tumor cells and their role in prostate cancer. <i>Asian Journal of Andrology</i> , 2019, 21, 24.	1.6	13
121	Hypertonicity-Affected Genes Are Differentially Expressed in Clear Cell Renal Cell Carcinoma and Correlate with Cancer-Specific Survival. <i>Cancers</i> , 2020, 12, 6.	3.7	13
122	Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab. <i>Cancers</i> , 2022, 14, 2972.	3.7	13
123	Met-RANTES improves acute-rejection-induced microvascular injury in rat small bowel transplantation. <i>Transplantation Proceedings</i> , 2002, 34, 1049.	0.6	12
124	Laser fragmentation of foreign bodies in the urinary tract: an in vitro study and clinical application. <i>World Journal of Urology</i> , 2010, 28, 177-180.	2.2	12
125	Biomechanical Proof of Barbed Sutures for the Efficacy of Laparoscopic Pyeloplasty. <i>Journal of Endourology</i> , 2012, 26, 540-544.	2.1	12
126	IMA901: a peptide vaccine in renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1329-1336.	4.1	12



#	ARTICLE	IF	CITATIONS
127	Metastasectomy for metastatic renal cell carcinoma in the era of modern systemic treatment: C&A reactive protein is an independent predictor of overall survival. International Journal of Urology, 2016, 23, 916-921.	1.0	12
128	The thermoexpandable nitinol stent: a long-term alternative in patients without nephropathy or malignancy. Scandinavian Journal of Urology, 2017, 51, 388-391.	1.0	12
129	Imaging response assessment of immunotherapy in patients with renal cell and urothelial carcinoma. Current Opinion in Urology, 2018, 28, 35-41.	1.8	12
130	Assessment of concomitant non-oncologic medication in patients with surgically treated renal cell carcinoma: impact on prognosis, cell-cycle progression and proliferation. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1835-1843.	2.5	12
131	Retroperitoneal Fibrosis and its Differential Diagnoses: The Role of Radiological Imaging. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2020, 192, 929-936.	1.3	12
132	Tumor-associated macrophages in clear cell renal cell carcinoma express both gastrin-releasing peptide and its receptor: a possible modulatory role of immune effectors cells. World Journal of Urology, 2010, 28, 335-341.	2.2	11
133	Modulation of Wnt and Hedgehog Signaling Pathways Is Linked to Retinoic Acid-Induced Amelioration of Chronic Allograft Dysfunction. American Journal of Transplantation, 2012, 12, 55-68.	4.7	11
134	Checkpoint modulation - A new way to direct the immune system against renal cell carcinoma. Human Vaccines and Immunotherapeutics, 2015, 11, 1201-1208.	3.3	11
135	Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?. Expert Review of Anticancer Therapy, 2017, 17, 357-368.	2.4	11
136	Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma. BMC Medicine, 2018, 16, 108.	5.5	11
137	Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275.. Journal of Clinical Oncology, 2019, 37, 4524-4524.	1.6	11
138	Laparoscopic versus Open Partial Nephrectomy: Comparison of Overall and Subgroup Outcomes. Anticancer Research, 2017, 37, 261-266.	1.1	11
139	Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?. Expert Review of Anticancer Therapy, 2013, 13, 1399-1408.	2.4	10
140	IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy. Future Oncology, 2014, 10, 937-948.	2.4	10
141	Predictive chromosomal clusters of synchronous and metachronous brain metastases in clear cell renal cell carcinoma. Cancer Genetics, 2014, 207, 206-213.	0.4	10
142	Contemporary management of acute kidney trauma. Journal of Acute Disease, 2016, 5, 29-36.	0.3	10
143	Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma. Expert Opinion on Biological Therapy, 2021, 21, 1215-1226.	3.1	10
144	Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma. BMC Urology, 2021, 21, 60.	1.4	10

#	ARTICLE	IF	CITATIONS
145	Abstract CT178: Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update and association between biomarkers and overall survival in CheckMate 275. , 2018, , .		10
146	Expression patterns and prognostic role of transketolase-like 1 in muscle-invasive bladder cancer. World Journal of Urology, 2015, 33, 1403-1409.	2.2	9
147	Cognitive versus Software-Assisted Registration: Development of a New Nomogram Predicting Prostate Cancer at MRI-Targeted Biopsies. Clinical Genitourinary Cancer, 2018, 16, e953-e960.	1.9	9
148	Molecular markers in disease detection and follow-up of patients with non-muscle invasive bladder cancer. Expert Review of Molecular Diagnostics, 2018, 18, 443-455.	3.1	9
149	Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases. Disease Markers, 2018, 2018, 1-5.	1.3	9
150	Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies. Clinical Genitourinary Cancer, 2019, 17, 65-71.	1.9	9
151	<sup>68</sup> Ga-PSMA-PET/CT-directed IGRT/SBRT for oligometastases of recurrent prostate cancer after initial surgery. Acta Oncologica, 2020, 59, 149-156.	1.8	9
152	A Rare Case of Synchronous Renal Cell Carcinoma of the Bladder Presenting with Gross Hematuria. Rare Tumors, 2013, 5, 72-74.	0.6	8
153	No influence of smoking status on the performance of urine markers for the detection of bladder cancer. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1367-1373.	2.5	8
154	Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study.. Journal of Clinical Oncology, 2021, 39, 327-327.	1.6	8
155	In vivo changes in acute rejection of rat small bowel allografts. Transplantation Proceedings, 2000, 32, 1247-1248.	0.6	7
156	Differential expression and clinical relevance of MUC1 in renal cell carcinoma metastasis. World Journal of Urology, 2016, 34, 1635-1641.	2.2	7
157	Variation across operating sites in urinary and sexual outcomes after radical prostatectomy in localized and locally advanced prostate cancer. World Journal of Urology, 2022, 40, 1437-1446.	2.2	7
158	Reply to Yongbao Wei, Ruochen Zhang, and Le Lin's Letter to the Editor re: Björke Ljungberg, Laurence Albiges, Yasmin Abu-Ghanem, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. 2022;82:e88. European Urology, 2022, 82, e111-e112.	1.9	7
159	Underestimated Risk of Bleeding after Male Transobturator Sling Procedure Caused by Early Re-Uptake of Anticoagulation. Urologia Internationalis, 2011, 86, 242-244.	1.3	6
160	76 Clinical and immunological monitoring of a multi-peptide vaccination trial in patients with stage III renal cell carcinoma. European Urology Supplements, 2012, 11, e76-e76a.	0.1	6
161	Peptide-Based Sandwich Immunoassay for the Quantification of the Membrane Transporter Multidrug Resistance Protein 1. Analytical Chemistry, 2018, 90, 5788-5794.	6.5	6
162	The prognostic value of fat invasion and tumor expansion in the hilar veins in pT3a renal cell carcinoma. World Journal of Urology, 2021, 39, 3367-3376.	2.2	6

#	ARTICLE	IF	CITATIONS
163	Chronic Periodontitis Does Not Impact Serum Levels of Prostate-specific Antigen. <i>Anticancer Research</i> , 2017, 37, 3163-3167.	1.1	6
164	Kidney-specific cadherin correlates with the ontogenetic origin of renal cell carcinoma subtypes: an indicator of a malignant potential?. <i>World Journal of Urology</i> , 2012, 30, 525-531.	2.2	5
165	Effect of radical prostatectomy on levels of cancer related epitopes in circulating macrophages of patients with clinically localized prostate cancer. <i>Prostate</i> , 2017, 77, 1251-1258.	2.3	5
166	Impact of variant microscopic interpretation of the uCyt+ immunocytological urine test for the detection of bladder cancer. <i>Diagnostic Cytopathology</i> , 2018, 46, 111-116.	1.0	5
167	Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma?. <i>Current Opinion in Urology</i> , 2021, 31, 270-275.	1.8	5
168	p53 is functionally inhibited in clear cell renal cell carcinoma (ccRCC): a mechanistic and correlative investigation into genetic and molecular characteristics. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3565-3576.	2.5	5
169	Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer. <i>Asian Journal of Andrology</i> , 2019, 21, 12.	1.6	5
170	Thioredoxin 1 (Trx1) is associated with poor prognosis in clear cell renal cell carcinoma (ccRCC): an example for the crucial role of redox signaling in ccRCC. <i>World Journal of Urology</i> , 2022, 40, 739-746.	2.2	5
171	Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies. <i>World Journal of Urology</i> , 2022, 40, 1175-1183.	2.2	5
172	Viral macrophage inflammatory protein-II improves acute rejection in allogeneic rat kidney transplants. <i>World Journal of Urology</i> , 2010, 28, 537-542.	2.2	4
173	Comment on "Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin". <i>Science Translational Medicine</i> , 2017, 9, .	12.4	4
174	Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. <i>European Urology Focus</i> , 2021, 7, 1084-1091.	3.1	4
175	Systemic treatment of advanced/metastatic renal cell carcinoma in the context of SARS-CoV-2 pandemic: recommendations from the interdisciplinary working group for renal tumors (IAG-N). <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3075-3078.	2.5	4
176	An evaluation of avelumab for the treatment of genitourinary tumors. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 971-979.	3.1	4
177	Outcomes of EAU-endorsed Live Surgical Events over a 5-year Period (2015-2020) and Updated Guidelines from the EAU Live Surgery Committee. <i>European Urology</i> , 2021, 80, 592-600.	1.9	4
178	Emphysematous Cystitis. <i>Deutsches Arzteblatt International</i> , 2020, 117, .	0.9	4
179	Oncologic Impact of Renal Tissue Adjacent to Renal Cell Carcinoma. <i>Anticancer Research</i> , 2016, 36, 2865-9.	1.1	4
180	T2 mapping for the characterization of prostate lesions. <i>World Journal of Urology</i> , 2022, 40, 1455-1461.	2.2	4

#	ARTICLE	IF	CITATIONS
181	Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma after Prior Therapy: Interim Results from the Noninterventional NORA Study. European Urology Focus, 2022, 8, 1289-1299.	3.1	4
182	A vaccine in renal cell carcinoma: are we nearing reality?. Expert Review of Anticancer Therapy, 2012, 12, 1503-1505.	2.4	3
183	Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors â€“ assessment of intra-tumour heterogeneity. BMC Medicine, 2016, 14, 201.	5.5	3
184	Re: Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. European Urology, 2016, 69, 538-539.	1.9	3
185	Molecular Signatures of Primary Human Spermatogonial Progenitors and Its Neighboring Peritubular Stromal Compartment. Stem Cells and Development, 2017, 26, 263-273.	2.1	3
186	Robotic Transrectal Computed Tomographic Ultrasound with Artificial Neural Network Analysis: First Validation and Comparison with MRI-Guided Biopsies and Radical Prostatectomy. Urologia Internationalis, 2022, 106, 90-96.	1.3	3
187	Health-related quality of life as a marker of treatment benefit with nivolumab in platinum-refractory patients with metastatic or unresectable urothelial carcinoma from CheckMate 275.. Journal of Clinical Oncology, 2017, 35, 4526-4526.	1.6	3
188	Age-Adapted Prostate Cancer Gene 3 Score Interpretation - Suggestions for Clinical Use. Clinical Laboratory, 2020, 66, .	0.5	3
189	Impact of altered Wnt1/ÃŸ-catenin expression on clinicopathology and prognosis in renal cell carcinoma.. Journal of Clinical Oncology, 2014, 32, 465-465.	1.6	3
190	Akt signalling parameters are different in oncocytomas compared to renal cell carcinoma. World Journal of Urology, 2012, 30, 353-359.	2.2	2
191	Reply. BJU International, 2013, 111, E20-1.	2.5	2
192	The Value and Evaluability of the PCA3 Urine Assay in Prostate Carcinoma is Independent of the Tumor Localization. Advances in Therapy, 2017, 34, 966-974.	2.9	2
193	Pembrolizumab for the treatment of renal cell carcinoma. Expert Opinion on Biological Therapy, 2021, 21, 1157-1164.	3.1	2
194	Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. European Urology, 2021, 80, 257-258.	1.9	2
195	Sequential treatment with pazopanib (PAZO) followed by nivolumab (NIVO) in patients with advanced or metastatic renal cell carcinoma (mRCC): Third interim results of the non-interventional study PAZOREAL.. Journal of Clinical Oncology, 2019, 37, 4574-4574.	1.6	2
196	Diagnostic benefit of multiparametric MRI over contrast-enhanced CT in patients with bladder cancer: A single-center 1-year experience. European Journal of Radiology, 2022, 146, 110059.	2.6	2
197	A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment Strategies. Frontiers in Oncology, 0, 12, .	2.8	2
198	Evaluation and management of a patient with a bladder mass of uncertain etiology. Nature Reviews Urology, 2008, 5, 509-514.	1.4	1

#	ARTICLE	IF	CITATIONS
199	1019 DOES BIOFILM RISK THE TREATMENT SUCCESS ATTAINED FROM THE TWO STEP IMPLANTATION OF A CHRONIC SACRAL NEUROMODULATOR?. Journal of Urology, 2010, 183, .	0.4	1
200	1994 PROSTATIC URETHRAL LIFT (PUL) PROVES EFFICACY IN LUTS TREATMENT OF BPH PATIENTS IN DAILY CLINIC PRACTICE OUTSIDE OF STUDIES. Journal of Urology, 2013, 189, .	0.4	1
201	Advanced Imaging and Possible Focal Therapy for Prostate Cancer. Current Surgery Reports, 2015, 3, 1.	0.9	1
202	Collection of real-world data on nivolumab's effectiveness in renal cell carcinoma: rationale for an observational study. Future Oncology, 2018, 14, 1023-1034.	2.4	1
203	Enzalutamide plus androgen-deprivation therapy in hormone-sensitive prostate cancer: new perspectives from a current Phase III clinical trial. Future Oncology, 2020, 16, 1511-1523.	2.4	1
204	Genetic analysis of primary renal cell carcinoma to determine treatment approaches. Expert Review of Precision Medicine and Drug Development, 2021, 6, 107-115.	0.7	1
205	On the probability of lymph node negativity in pN0-staged prostate cancerâ€”a theoretically derived rule of thumb for adjuvant needs. Strahlentherapie Und Onkologie, 2022, 198, 690-699.	2.0	1
206	Adjuvant multi-peptide vaccination in high-risk renal cell carcinoma.. Journal of Clinical Oncology, 2010, 28, e15051-e15051.	1.6	1
207	Five years into the national second-opinion project of the German Testicular Cancer Group (GCTSG): Impact on guideline implementation and the quality of care for testicular cancer patients.. Journal of Clinical Oncology, 2012, 30, 4530-4530.	1.6	1
208	Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL.. Journal of Clinical Oncology, 2018, 36, 4584-4584.	1.6	1
209	Determination of Free-PSA (fPSA) and fPSA/PSA-Ratio Using A Point-of-Care Device. Clinical Laboratory, 2019, 65, .	0.5	1
210	Is a single portal venous phase in contrast-enhanced CT sufficient to detect metastases or recurrence in clear cell renal cell carcinoma? â€” a single-center retrospective study. Cancer Imaging, 2022, 22, 9.	2.8	1
211	Characterization of Genetic Heterogeneity in Recurrent Metastases of Renal Cell Carcinoma. Cancers, 2021, 13, 6221.	3.7	1
212	Re: Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma. European Urology, 2008, 54, 1200-1201.	1.9	0
213	MULTIVARIATE ANALYSIS OF PATIENTS TREATED WITH RADICAL CYSTECTOMY EVALUATING NEWLY PROPOSED PROGNOSTIC FACTORS FOR BLADDER CANCER SPECIFIC SURVIVAL. Journal of Urology, 2008, 179, 550-551.	0.4	0
214	Impact of preoperative haemoglobin concentrations on the efficiency of KTP-laser vaporization of the prostate. World Journal of Urology, 2009, 27, 405-409.	2.2	0
215	630 TFE3-TRANSLOCATION TUMOURS ARE MORE FREQUENT IN YOUNG ADULTS THAN IN OLD RENAL CELL CARCINOMA PATIENTS. Journal of Urology, 2010, 183, .	0.4	0
216	1773 IS VEGF TARGETED THERAPY IN RENAL CELL CARCINOMA WITH LATE METASTASES TO THE PANCREAS AND THE THYROID GLAND REASONABLE? â€” A STUDY OF CHROMOSOMAL IMBALANCES. Journal of Urology, 2011, 185, .	0.4	0

#	ARTICLE	IF	CITATIONS
217	246 SPECIFIC CD4+ AND CD8+ T CELLS ACTIVATION BY MULTI-PEPTIDE VACCINATION IN PATIENTS WITH STAGE III RENAL CELL CARCINOMA. Journal of Urology, 2011, 185, .	0.4	0
218	123 ASSESSMENT OF MOLECULAR DIFFERENCES BETWEEN EARLY AND LATELY DEVELOPED RENAL CELL CARCINOMA. Journal of Urology, 2011, 185, .	0.4	0
219	V1559 COMBINED THERAPY OF STRESS URINARY INCONTINENCE AND ERECTILE DYSFUNCTION WITH THE IMPLANTATION OF ADVANCE (XP) AND AMS 700 IN A SINGLE PROCEDURE. Journal of Urology, 2012, 187, .	0.4	0
220	1550 NANOTECHNOLOGY: 1.2F BASKETS FURTHER ENHANCE IRRIGATION FLOW IN FLEXIBLE URETERORENOSCOPY. Journal of Urology, 2013, 189, .	0.4	0
221	303 IMPACT OF ALTERED WNT1/ $\beta$ 2-CATENIN EXPRESSION ON CLINICOPATHOLOGY AND PROGNOSIS IN RENAL CELL CARCINOMA. Journal of Urology, 2013, 189, .	0.4	0
222	Optimizing treatment of seminoma stage IIA/B step by step. Annals of Oncology, 2013, 24, 2463.	1.2	0
223	Re: Validation of a Cell-cycle Progression Gene Panel to Improve Risk Stratification in a Contemporary Prostatectomy Cohort. European Urology, 2014, 65, 248.	1.9	0
224	How far is the horizon? From current targets to future drugs in advanced renal cancer. World Journal of Urology, 2014, 32, 69-77.	2.2	0
225	MP30-05 DETECTION OF TRANSLOCATION TUMOURS ON RENAL CELL CARCINOMA TISSUE MICRO ARRAYS BY FISH. Journal of Urology, 2014, 191, .	0.4	0
226	MP61-03 EVALUATION OF LACTATE TRANSPORTERS AS POTENTIAL THERAPEUTIC TARGET IN UROTHELIAL CARCINOMA. Journal of Urology, 2016, 195, .	0.4	0
227	MP34-09 MEMOKATH 051 â€“ A SAVE ALTERNATIVE FOR TREATMENT OF URETERIC STRICTURES. Journal of Urology, 2016, 195, .	0.4	0
228	MP64-17 REDUCTION OF POSITIVE SURGICAL MARGINS DUE TO A SIMPLIFIED NEUROSAFE TECHNIQUE. Journal of Urology, 2017, 197, .	0.4	0
229	AGS-003 combined with sunitinib for the precision treatment of metastatic renal cell carcinoma. Expert Review of Precision Medicine and Drug Development, 2017, 2, 243-248.	0.7	0
230	Editorial: Standard and future in the treatment of renal cell carcinoma. Current Opinion in Urology, 2021, 31, 226-227.	1.8	0
231	Met-RANTES verbessert die mikropilläre Perfusion während der akuten Abstoßung am DA1/4ndarmtransplantat der Ratte. Langenbecks Archiv Für Chirurgie Supplement, 2002, , 271-273.	0.0	0
232	Einmalige Vorbehandlung der Spendergefäße mit einem Decoy-Oligonukleotid gegen STAT-1 verbessert die mukosale Perfusion und reduziert die CSA-Dosis im allogenen DA1/4ndarmtransplantationsmodell der Ratte. Langenbecks Archiv Für Chirurgie Supplement, 2004, , 335-336.	0.0	0
233	822: Botulinum Toxin Type a (Dysport®) for the Treatment of Children with Neurogenic Detrusor Overactivity Due to Myelodysplasia (MMC). Journal of Urology, 2007, 177, 274-274.	0.4	0
234	Association of high cytoplasmic expression of p27 Kip1 on cancer-specific survival in clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2012, 30, 418-418.	1.6	0

#	ARTICLE	IF	CITATIONS
235	Abstract 2002: OCT-3/4 expression is associated with high levels of the pro-apoptotic BH3 only protein NOXA in testicular germ cell tumors (TGCTs). , 2012, , .		0
236	Use of preoperative C-reactive protein to improve predictive accuracy in clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2013, 31, 474-474.	1.6	0
237	CpG island hypermethylation of corticotropin-releasing hormone-binding protein in kidney cancer and association with clinicopathological parameters.. Journal of Clinical Oncology, 2013, 31, 414-414.	1.6	0
238	Fournierâ€™s Gangrene. , 2014, , 365-368.		0
239	Impact on clinical prognosis using DNA methylation of the SLC16A3 promoter and expression of the human lactate transporter MCT4 in renal cancer.. Journal of Clinical Oncology, 2014, 32, 452-452.	1.6	0
240	Abstract 1192: Establishment and characterization of a new patient-derived renal cell carcinoma xenograft panel. , 2014, , .		0
241	Abstract 1693: Nicotinamide N-methyltransferase in clear cell renal cell carcinoma primary tumors and metastases. , 2016, , .		0
242	Abstract 1632: Identification and analysis of EGLN3 as tumor-associated peptide in ccRCC. , 2017, , .		0
243	Abstract 5219: Characterization of the breast cancer resistance protein BCRP in clear cell renal cell carcinoma. , 2017, , .		0
244	Abstract 1843: Intratumoral heterogeneity of renal cancer is related to differences in drug response and development of therapy resistance. , 2017, , .		0
245	Abstract 3485: Transcriptomic and metabolomic profiles in renal cell carcinoma (RCC) tumors reflect ontogeny of RCC subtypes. , 2018, , .		0
246	Abstract 5687: Integrative -omics analysis to identify drug targets for ccRCC immunotherapy. , 2018, , .		0
247	Impact of 68Ga-PSMA PET/CT on treatment in patients with recurrent prostate cancer: comparison with 11C-choline PET and diagnostic CT. , 2019, 58, .		0
248	A prospective, open label, multicenter, randomized phase II trial: Sequential therapy with bevacizumab, RAD001 (everolimus) and axitinib in metastatic renal cell carcinoma (mRCC) (BERAT study).. Journal of Clinical Oncology, 2019, 37, e16097-e16097.	1.6	0
249	Abstract 2529: Comprehensive genomic analyses of a case series of bilateral renal cell carcinoma. , 2019, , .		0
250	Analysis of clinical outcomes according to response status in prospective clinical trials of atezolizumab (atezo) in pretreated locally advanced/metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2020, 38, 492-492.	1.6	0